Orchestra BioMed Holdings, Inc. (OBIO)
| Market Cap | 355.22M +73.7% |
| Revenue (ttm) | 31.98M +986.1% |
| Net Income | -59.57M |
| EPS | -1.00 |
| Shares Out | 60.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 231,573 |
| Open | 6.07 |
| Previous Close | 6.09 |
| Day's Range | 5.84 - 6.08 |
| 52-Week Range | 3.46 - 6.50 |
| Beta | 0.52 |
| Analysts | Strong Buy |
| Price Target | 12.43 (+110.32%) |
| Est. Earnings | Nov 13, 2026 |
About OBIO
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a b... [Read more]
Financial Performance
In 2025, Orchestra BioMed Holdings's revenue was $33.48 million, an increase of 1169.22% compared to the previous year's $2.64 million. Losses were -$52.96 million, -13.22% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for OBIO stock is "Strong Buy." The 12-month stock price target is $12.43, which is an increase of 110.32% from the latest price.
News
Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Presentation will highlight Virtue SAB's fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall. ...
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed surpasses full enrollment in BACKBEAT trial
Orchestra BioMed (OBIO) announced that it has surpassed full enrollment in the BACKBEAT Global Pivotal Trial, exceeding its previously announced target of 316 randomized patients. The BACKBEAT Trial i...
Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy
330 patients randomized as of September 30, 2026, surpassing full trial enrollment target Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consid...
OBIO's Capital Access Advisory Program (CAAP®) Reaches Milestone with $1 Billion Raised by High-Growth Life Sciences and Health Tech Ventures
TORONTO--(BUSINESS WIRE)--OBIO® companies supported through its Capital Access Advisory Program have now collectively raised over $1 billion in capital.
Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026
NEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to pa...
Orchestra BioMed receives $6.1M milestone payment from Haemonetics
Orchestra BioMed (OBIO) announced the receipt of $6.1M as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical by Haemonetics (HAE). This second paym...
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million Company remains eligible for up to approximately $10 million in ad...
Orchestra BioMed price target raised to $11 from $10 at B. Riley
B. Riley raised the firm’s price target on Orchestra BioMed (OBIO) to $11 from $10 and keeps a Buy rating on the shares after assuming coverage of the name. Orchestra…
Orchestra BioMed Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference
The presentation highlighted a partnership-driven model advancing two pivotal-stage programs: AVIM therapy for hypertension in pacemaker patients and Virtue SAB for coronary artery disease. Both programs target large, established markets, are supported by major strategic partners, and are on track for key clinical and regulatory milestones.
Orchestra BioMed upgraded to Buy from Neutral at BTIG
BTIG analyst Marie Thibault upgraded Orchestra BioMed (OBIO) to Buy from Neutral with a $10 price target The firm is “more constructive” on the stock following recent management commentary detailing…
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pa...
Orchestra BioMed to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
NEW HOPE, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference
NEW HOPE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed price target raised to $10 from $9 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Orchestra BioMed (OBIO) to $10 from $9 and keeps an Overweight rating on the shares following quarterly results and…
Orchestra BioMed reports Q2 EPS (37c), consensus (38c)
Reports Q2 revenue $88,000, consensus $118,170. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed (OBIO), stated, “The second quarter brought clarity on both the timeline and the...
Orchestra BioMed Holdings Quarterly report: Q2 2026
Orchestra BioMed Holdings has published its Q2 2026 quarterly earnings report on August 10, 2026.
Orchestra BioMed Holdings Earnings release: Q2 2026
Orchestra BioMed Holdings released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Orchestra BioMed joins Russell 3000, Russell 2000 Indexes
Orchestra BioMed (OBIO) announced that it has joined the broad-market Russell 3000 Index and the small-cap Russell 2000 Index at the conclusion of the 2026 Russell indexes reconstitution, effective af...
Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes
NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...
Orchestra BioMed Holdings Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved and an annual frequency set for future compensation votes. No questions were raised by shareholders during the session.
Orchestra BioMed Holdings Transcript: Sidoti Small-Cap Virtual Investor Conference
Two flagship cardiovascular device therapies are advancing through pivotal trials, supported by strong partnerships with Medtronic and Terumo and robust financial backing. Key milestones include imminent BACKBEAT trial data and ongoing Virtue SAB enrollment, with commercialization targeted for 2028.
Orchestra BioMed Holdings Proxy statement: Proxy filing
Orchestra BioMed Holdings filed a proxy statement on June 16, 2026, providing details for shareholder voting and corporate governance matters.
Orchestra BioMed Holdings Transcript: Jefferies Global Healthcare Conference 2026
The session highlighted a partnership-driven model focused on R&D and pivotal trials, with major programs in hypertension therapy and drug delivery platforms. Key milestones include upcoming BackBeat trial data and Virtue enrollment completion, both with strong commercial potential and strategic partnerships.
Orchestra BioMed Holdings Slides: Corporate presentation
Orchestra BioMed Holdings has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.